MedTrace Logo

Biomarkers of Oat Product Intake: The BiOAT Marker Study

NCT05511077 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2023-02-21

No results posted yet for this study

Summary

The aim of this project is to evaluate avenanthramides and avenacosides and their metabolites as specific biomarkers of oat product intake in humans. Biomarkers will be evaluated after i) a single dose through a single meal based on a solid and a liquid oat-based product (pharmacokinetic study) ii) week-long consumption at three different intake levels (dose-response). The study will be carried out as a two-way cross-over design with two different oat products, liquid or solid, where each product is provided 3 times per day during 5 days per product. A wash-out period of 8 days where participants consume their habitual diet is implemented. The first day of study meal intervention includes postprandial measurements during 8 hours.

Conditions

  • Healthy

Interventions

OTHER

Diet

Intervention products consist of two different oat products, one solid and one liquid. The content of oat in the products differs.

Sponsors & Collaborators

  • Oatly Group Inc

    collaborator UNKNOWN

  • Chalmers University of Technology

    lead OTHER

Principal Investigators

  • Rikard Landberg, Dr · Chalmers University of Technology

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-09
Primary Completion
2022-12-19
Completion
2022-12-19

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05511077 on ClinicalTrials.gov